



ENBREL® (etanercept) SmartClic® offers a new treatment device option for rheumatoid arthritis patients taking this injectable medicine.

- ENBREL® is a TNF (tumour necrosis factor inhibitor) indicated for treatment Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), moderate to severe paediatric and adult Plaque Psoriasis (PsO), Juvenile Idiopathic Arthritis (JIA), and active non-radiographic axial spondyloarthritis.
- ENBREL SMARTCLIC is the latest self-injecting device for patients taking ENBREL.

SYDNEY, AUSTRALIA <<28 March2022>> — Pfizer is pleased to announce the launch of ENBREL® SmartClic® in Australia- a new self-injecting device for ENBREL® patients, with a companion smartphone app. ENBREL®, is a tumour necrosis factor (TNF) inhibitor indicated for the treatment of diseases such as Rheumatoid Arthritis (RA), which currently affects close to half a million Australians¹, with numbers expected to increase.

“The TGA listing of Enbrel SmartClic and PBS listing of the dose dispenser cartridge reinforces Pfizer’s commitment to developing new digital health technologies designed around the needs of patients with chronic inflammatory diseases,” said Pfizer Australia’s Medical Affairs Lead for Inflammation and Immunology, Dr David Witcombe.

“Whilst self-injection is recognised as helping patients with auto-immune diseases like RA to gain control of where and when they administer their treatment, numerous factors have been identified which may affect a patient’s self-injection experience.

“These include physical constraints – common disease symptoms such as hand dexterity problems and pain can make self-injection difficult – through to injection anxiety” Dr Witcombe said.

ENBREL® SmartClic®, is an automated, re-usable self-injection device. The various features of SmartClic® such as one button to initiate injection, a large grip* (compared to the Enbrel Auto-Injector) and injection speed control help patients with their self-injection.

SmartClic® can be paired with the companion mobile phone application to access a range of optional features. From setting reminders, recording and tracking injection history, tracking injection sites and creating streamlined reports – with all data synced to and available on the patient’s smart phone – which can be shared with their healthcare professional.

Patients taking Enbrel are recommended to see their doctor for more information on SmartClic®.

++
ENDS

About Enbrel Dose-Dispenser Cartridge PBS: [Pharmaceutical Benefits Scheme \(PBS\) | PBS Medicine Search](#) & Enbrel SmartClic® TGA registration:[378335](#) | [Therapeutic Goods Administration \(TGA\)](#)

SmartClic, an automated reusable self-injection device plus companion smartphone app

Enbrel is a tumour necrosis factor (TNF) blocker indicated for the treatment of Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis.

Enbrel Consumer Medicine Information <<
<https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-CMI-05236-3&d=20220306172310101>>>for additional safety information on ENBREL SMARTCLIC®.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. For more information, visit:

www.pfizer.com.au

Media contacts:

Pfizer Australia & NZ Corporate Affairs
mediaANZ@pfizer.com
+61 466 641 224

Reference

1. Time to Move: Rheumatoid Arthritis A national strategy to reduce a costly burden. Arthritis Australia, 2014. Accessed at: https://arthritisaustralia.com.au/wordpress/wp-content/uploads/2017/09/Final_Time_to_Move_Rheumatoid_arthritis.pdf February 2022.

Consumer Medicine Information

<https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-CMI-05236-3&d=20220306172310101>

® Registered Trademark.

PP-ENB-AUS-0848